Status: Not yet recruiting
Vorinostat for Graft-versus-host Disease (GVHD) Prevention in Non-Malignant Adolescent and Young Adults (AYA) Population
This is a single-arm, open label, phase 2 study to determine the safety and efficacy of vorinostat without serotherapy as GVHD prophylaxis when combined with either tacrolimus and methotrexate or post-transplant cyclophosphamide, tacrolimus, and mycophenolate in patients aged 1 to 26 years of age with non-malignant disorders undergoing bone marrow transplant following myeloablative conditioning.
Participants needed: 55
Trial details
Phase: Phase 2Age: 1-26Biological sex: AllType: InterventionalSponsor: Sung Won ChoiUpdated: Jun 30, 2026Locations: 1
Eligibility criteria
Primary Immunodeficiency/Primary Immune regulatory disorders [+14]
Diagnosis of idiopathic severe aplastic anemia [+15]